ChemicalBook > CAS DataBase List > Glenzocimab
Glenzocimab
- Product Name
- Glenzocimab
- CAS No.
- 2101829-58-5
- Chemical Name
- Glenzocimab
- Synonyms
- ACT017;Glenzocimab;Glenzocimab (anti-GP6);Research Grade Glenzocimab;Research Grade Glenzocimab (DHJ60601)
- CBNumber
- CB18081129
- Formula Weight
- 0
- MOL File
- Mol file
More
Less
Glenzocimab Property
- form
- Liquid
- color
- Colorless to light yellow
More
Less
Glenzocimab Chemical Properties,Usage,Production
Uses
ACT017 is a Fab fragment of humanized anti-GPVI monoclonal antibody. ACT017 inhibits collagen-induced platelet aggregation. ACT017 has the potential for the research of acute ischemic stroke[1][2].
in vivo
ACT017 (1-8 mg/kg; i.v.) inhibits collagen-induced platelet aggregation in cynomolgus monkeys[2].
| Animal Model: | Cynomolgus monkeys[2] |
| Dosage: | 1-8 mg/kg |
| Administration: | I.v. |
| Result: | Reversibly inhibited collagen-induced platelet aggregation, at 2 to 8 mg/kg doses, collagen-induced platelet aggregation measured 0.5 hour after the end of the administration was fully inhibited for all cynomolgus. |
References
[1] Wichaiyo S, et al. Glenzocimab: A GPVI (Glycoprotein VI)-Targeted Potential Antiplatelet Agent for the Treatment of Acute Ischemic Stroke. Stroke. 2022 Nov;53(11):3506-3513. DOI:10.1161/STROKEAHA.122.039790
[2] Lebozec K, et al. Design, development and characterization of ACT017, a humanized Fab that blocks platelet's glycoprotein VI function without causing bleeding risks. MAbs. 2017 Aug/Sep;9(6):945-958. DOI:10.1080/19420862.2017.1336592
Glenzocimab Preparation Products And Raw materials
Raw materials
Preparation Products
More
Less
Glenzocimab Suppliers
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com
- Country
- United States
- ProdList
- 32435
- Advantage
- 58
2101829-58-5, GlenzocimabRelated Search:
Loncastuximab
Xentuzumab
Voxalatamab
Ebronucimab
Sasanlimab
Radretumab
Zolimomabaritox
Imciromab
Istiratumab
Fezakinumab